Armata Pharmaceuticals, Inc.

DB:TG1N Stock Report

Market Cap: €67.8m

Armata Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Deborah Birx

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage17.8%
CEO tenure1.4yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Deborah Birx's remuneration changed compared to Armata Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$41m

Jun 30 2024n/an/a

-US$67m

Mar 31 2024n/an/a

-US$80m

Dec 31 2023US$1mUS$252k

-US$69m

Compensation vs Market: Deborah's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD469.36K).

Compensation vs Earnings: Insufficient data to compare Deborah's compensation with company performance.

CEO

Deborah Birx (67 yo)

1.4yrs

Tenure

US$1,411,908

Compensation

Dr. Deborah L. Birx, M.D., serves as CEO & Director of Armata Pharmaceuticals, Inc. since July 11, 2023. She is Member of Palantir Federal Advisory Board at Palantir Technologies Inc. since October 2022. S...

Leadership Team

NamePositionTenureCompensationOwnership
Deborah Birx
CEO & Director1.4yrsUS$1.41mno data
David House
Senior VP of Finance & Principal Financial Officerless than a yearno datano data
Peter Hubbard
Vice President of Operationsless than a yearno datano data
Pierre Kyme
Chief Business Officerless than a yearno data0.028%
€ 18.7k

0.7yrs

Average Tenure

Experienced Management: TG1N's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Deborah Birx
CEO & Director1.4yrsUS$1.41mno data
Joseph Patti
Independent Director5.6yrsUS$86.19k0%
€ 0
Jules Haimovitz
Independent Director3.7yrsUS$74.88k0%
€ 0
Odysseas Kostas
Independent Director4.8yrsUS$64.19k0%
€ 0
Athena Papas
Member of C16G2 Clinical Advisory Boardno datano datano data
Sarah Schlesinger
Independent Director4.8yrsUS$66.19k0%
€ 0
Todd Peterson
Independent Director5.2yrsUS$73.19k0%
€ 0
Robin Kramer
Independent Chairman of the Board4yrsUS$105.50k0%
€ 0
James Bader
Member of C16G2 Clinical Advisory Boardno datano datano data
Ann Griffen
Member of C16G2 Clinical Advisory Boardno datano datano data
Mark Wolff
Member of C16G2 Clinical Advisory Boardno datano datano data
Domenick Zero
Member of C16G2 Clinical Advisory Boardno datano datano data

4.8yrs

Average Tenure

64yo

Average Age

Experienced Board: TG1N's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Armata Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.